|
Radiologic response
|
---|
|
Complete response
|
Partial response
|
Stable disease
|
Progressive disease
|
---|
Resectable
|
0%
|
11%
|
77%
|
11%
|
[0–0%]
|
[8–16%]
|
[62–89%]
|
[4–19%]
|
I
2 = 0%
|
I
2 = 10.6%
|
I
2 = 85.12%
|
I
2 = 82.31%
|
(n = 8)
|
(n = 8)
|
(n = 9)
|
(n = 11)
|
Borderline resectable
|
1%
|
20%
|
56%
|
19%
|
[0–4%]
|
[8–35%]
|
[47–64%]
|
[11–28%]
|
I
2 = 52.03%
|
I
2 = 84.28%
|
I
2 = 33.25%
|
I
2 = 58.95%
|
(n = 8)
|
(n = 8)
|
(n = 8)
|
(n = 9)
|
Locally advanced
|
1%
|
28%
|
48%
|
20%
|
[0–3%]
|
[21–35%]
|
[38–58%]
|
[13–29%]
|
I
2 = 57.02%
|
I
2 = 82.61%
|
I
2 = 88.09%
|
I
2 = 89.43%
|
(n = 17)
|
(n = 19)
|
(n = 17)
|
(n = 18)
|
BR + LA
|
0%
|
20%
|
59%
|
14%
|
[0–1%]
|
[11–31%]
|
[49–69%]
|
[8–22%]
|
I
2 = 7.57%
|
I
2 = 84.70%
|
I
2 = 76.89%
|
I
2 = 72.59%
|
(n = 16)
|
(n = 16)
|
(n = 16)
|
(n = 16)
|
All patients
|
0%
|
20%
|
59%
|
16%
|
[0–1%]
|
[16–25%]
|
[54–65%]
|
[12–20%]
|
I
2 = 38.25%
|
I
2 = 81.52%
|
I
2 = 85.12%
|
I
2 = 82.84%
|
(n = 52)
|
(n = 56)
|
(n = 56)
|
(n = 62)
|
- Values in [] reflect the 95% confidence interval. I
2 is a quantitative indicator of heterogeneity among the studies, and n refers to the number of studies reporting the outcomes